174 related articles for article (PubMed ID: 26102535)
21. A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital.
Jiang C; Whitmore-Sisco L; Gaur AH; Adderson EE;
Vaccine; 2018 Jan; 36(2):214-219. PubMed ID: 29217370
[TBL] [Abstract][Full Text] [Related]
22. Tetanus, diphtheria, pertussis vaccination coverage before, during, and after pregnancy - 16 States and New York City, 2011.
Ahluwalia IB; Ding H; D'Angelo D; Shealy KH; Singleton JA; Liang J; Rosenberg KD;
MMWR Morb Mortal Wkly Rep; 2015 May; 64(19):522-6. PubMed ID: 25996094
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
24. Pertussis antibodies and vaccination coverage among healthcare professionals in Brazil is inadequate: A cross-sectional serological study.
Cardona RSB; Weckx LY; de Moraes-Pinto MI; Ramos BCF; Dos Santos ARA; Spina FG; de Araújo BC; Clemens R; Clemens SAC
Vaccine; 2023 Sep; 41(39):5769-5774. PubMed ID: 37573201
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart.
Embree J; Law B; Voloshen T; Tomovici A
Clin Vaccine Immunol; 2015 Mar; 22(3):282-90. PubMed ID: 25540274
[TBL] [Abstract][Full Text] [Related]
26. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants.
Healy CM; Rench MA; Baker CJ
Clin Infect Dis; 2013 Feb; 56(4):539-44. PubMed ID: 23097585
[TBL] [Abstract][Full Text] [Related]
27. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(25):468-70. PubMed ID: 22739778
[TBL] [Abstract][Full Text] [Related]
28. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population.
Tseng HF; Sy LS; Qian L; Marcy SM; Jackson LA; Glanz J; Nordin J; Baxter R; Naleway A; Donahue J; Weintraub E; Jacobsen SJ;
Clin Infect Dis; 2013 Feb; 56(3):315-21. PubMed ID: 23196953
[TBL] [Abstract][Full Text] [Related]
29. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
[TBL] [Abstract][Full Text] [Related]
30. Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US.
Plosker GL
BioDrugs; 2009; 23(4):253-67. PubMed ID: 19697967
[TBL] [Abstract][Full Text] [Related]
31. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
[TBL] [Abstract][Full Text] [Related]
32. High need for MMR vaccination in HIV infected adults in Austria.
Grabmeier-Pfistershammer K; Poeppl W; Herkner H; Touzeau-Roemer V; Huschka E; Rieger A; Burgmann H
Vaccine; 2014 Oct; 32(45):6020-3. PubMed ID: 25203449
[TBL] [Abstract][Full Text] [Related]
33. Randomized clinical trial of the safety and immunogenicity of the Tdap vaccine in pregnant Mexican women.
Villarreal Pérez JZ; Ramírez Aranda JM; de la O Cavazos M; Zamudio Osuna MJ; Perales Dávila J; Ballesteros Elizondo MR; Gómez Meza MV; García Elizondo FJ; Rodríguez González AM
Hum Vaccin Immunother; 2017 Jan; 13(1):128-135. PubMed ID: 27686182
[TBL] [Abstract][Full Text] [Related]
34. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
Dylag AM; Shah SI
Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
[TBL] [Abstract][Full Text] [Related]
35. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?
Halperin SA; Sweet L; Baxendale D; Neatby A; Rykers P; Smith B; Zelman M; Maus D; Lavigne P; Decker MD
Pediatr Infect Dis J; 2006 Mar; 25(3):195-200. PubMed ID: 16511379
[TBL] [Abstract][Full Text] [Related]
36. Tdap vaccine attitudes and utilization among pregnant women from a high-risk population.
Dempsey AF; Brewer SE; Sevick C; Pyrzanowski J; Mazzoni S; O'Leary ST
Hum Vaccin Immunother; 2016 Apr; 12(4):872-8. PubMed ID: 26430729
[TBL] [Abstract][Full Text] [Related]
37. Adequate tetanus but poor diphtheria and pertussis response to a Tdap booster in adolescents with juvenile systemic lupus erythematosus.
Peracchi OA; Nicácio AAM; Yamada J; Len CA; Moraes-Pinto MI; Terreri MT
Lupus; 2021 Feb; 30(2):299-306. PubMed ID: 33197362
[TBL] [Abstract][Full Text] [Related]
38. Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients.
Sticchi L; Bruzzone B; Caligiuri P; Rappazzo E; Lo Casto M; De Hoffer L; Gustinetti G; Viscoli C; Di Biagio A
Hum Vaccin Immunother; 2015; 11(1):263-9. PubMed ID: 25483544
[TBL] [Abstract][Full Text] [Related]
39. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.
Mertsola J; Van Der Meeren O; He Q; Linko-Parvinen A; Ramakrishnan G; Mannermaa L; Soila M; Pulkkinen M; Jacquet JM
Clin Infect Dis; 2010 Sep; 51(6):656-62. PubMed ID: 20704493
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials.
Van Damme P; McIntyre P; Grimprel E; Kuriyakose S; Jacquet JM; Hardt K; Messier M; Van Der Meeren O
Vaccine; 2011 Aug; 29(35):5932-9. PubMed ID: 21718738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
